Medtronic reported strong Q1 FY26 results with $8.58B in revenue and consistent organic growth across cardiovascular and diabetes segments. GAAP EPS rose to $0.81 while non-GAAP EPS reached $1.26, prompting an upward revision of full-year earnings guidance.
Q1 revenue reached $8.58 billion, up 8.4% YoY as reported
Net income of $1.04 billion with GAAP EPS at $0.81
Raised FY26 non-GAAP EPS guidance to $5.60–$5.66
Cardiac Ablation Solutions and Diabetes segments showed strong double-digit growth
Medtronic reaffirmed its FY26 organic revenue growth target of ~5% and raised its non-GAAP EPS guidance to a range of $5.60 to $5.66, reflecting stronger-than-expected Q1 performance and a more favorable outlook on tariffs.
Visualization of income flow from segment revenue to net income